Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
5.3
4.1
Journals
Metabolites
Special Issues
Novel Metabolomics and Techniques for Metabolic Disorders in Intestinal Microbiota
share announcement

Novel Metabolomics and Techniques for Metabolic Disorders in Intestinal Microbiota

A special issue of Metabolites (ISSN 2218-1989). This special issue belongs to the section "Microbiology and Ecological Metabolomics".

Deadline for manuscript submissions: 31 August 2024 | Viewed by 4596

Special Issue Editors

Dr. Guozhu Ye

E-Mail Website
Guest Editor
Key Laboratory of Urban Environment and Health, Institute of Urban Environment, Chinese Academy of Sciences, 1799 Jimei Road, Xiamen 361021, China
Interests: metabolomics; functional metabolomics; LC-MS; GC-MS; intestinal micro-biota; metabolism; molecular pathophysiology; molecular toxicology
Dr. Zeming Wu

E-Mail Website
Guest Editor
iPhenome Biotechnology, 57 Xinda Road, Dalian 116085, China
Interests: metabolipidomics; quantitative proteomics; untargeted screening; LC-MS-based in vitro diagnostic; bioinformatics

Special Issue Information

Dear Colleagues,

As the largest microecosystem in human body, intestinal microbiota co-evolved with the host for a long time, and has vita physiological and pathological roles, such as mediating metabolism, intestinal barrier function, immune balance, biological rhythm, and neurobehavior. As host signaling molecules and/or biocatalytic substrates, intestinal flora metabolites can be absorbed through the intestine or directly act on the intestine to affect physiological and/or pathological processes in vivo. Studies have shown that intestinal flora metabolites are closely related to a variety of diseases, including inflammatory bowel disease, obesity, diabetes, cardiovascular disease, cancer, etc., which has attracted increasing attention and formed academic hot spots.

Metabolites are end products of physiological activities, and their contents are final responses of biological system to gene and/or environmental alterations. Therefore, changes in metabolites are closest to the phenotype compared to those in genes/proteins. However, due to diverse structures, heterogenous physicochemical property, and wide concentration range of metabolome, profiling intestinal flora metabolites with a wide and/or deep coverage is still a great challenge. Moreover, due to the gap between different disciplines, integrating metabolomics data on intestinal microbiota with those from other omics and disciplines is still not effective. Therefore, we hope that this Special Issue can promote the development and application of metabolomic methods for studies on metabolic disorders in intestinal microbiota.

Contributions on following subject areas are welcome, but not limited to:

  1. Wider and/or deeper metabolome coverage of intrinsic metabolites in intestinal microbiota. The metabolites include virulence factors (such as products of lipopolysaccharide and peptidoglycan), and quorum sensing molecules (e.g., acylated homoserine lactone). Special attention is paid to highly bioactive metabolites derived from intrinsic metabolism of intestinal microbiota, including Lipid X, Lipid IVA, lipoteichoic acid, oligopeptides and derivatives (such as muramyl dipeptides, γ-D-glutamyl-meso-diaminopimelic acid), and acylated homoserine lactone.
  2. Wider and/or deeper metabolome coverage of microbial and host co-metabolites. Special attention is paid to highly bioactive metabolites, such as short-chain organic acids, bile acids, products of tryptophan, and metabolites involved in trimethylamine metabolism.
  3. Pathological/toxicological effect-oriented discovery of metabolic reprogramming, bioactive metabolites and relevant regulatory targets in intestinal microbiota. For example, the discovery of quorum sensing molecules and their metabolic pathways under specific stress conditions or pathological conditions.

Dr. Guozhu Ye
Dr. Zeming Wu
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Metabolites is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • intestinal microbiota
  • metabolomics
  • LC-MS
  • GC-MS
  • virulence factor
  • microbial and host co-metabolite
  • metabolic reprogramming
  • metabolic disorders

Published Papers (3 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

19 pages, 2508 KiB  
Article
HMOs Impact the Gut Microbiome of Children and Adults Starting from Low Predicted Daily Doses
by Danica Bajic, Frank Wiens, Eva Wintergerst, Stef Deyaert, Aurélien Baudot and Pieter Van den Abbeele
Metabolites 2024, 14(4), 239; https://0-doi-org.brum.beds.ac.uk/10.3390/metabo14040239 - 20 Apr 2024
Viewed by 527
Abstract
Recent studies suggest that the dietary intake of human milk oligosaccharides (HMOs) provides health benefits from infancy up to adulthood. Thus far, beneficial changes in the adult gut microbiome have been observed at oral doses of 5–20 g/day of HMOs. Efficacy of lower [...] Read more.
Recent studies suggest that the dietary intake of human milk oligosaccharides (HMOs) provides health benefits from infancy up to adulthood. Thus far, beneficial changes in the adult gut microbiome have been observed at oral doses of 5–20 g/day of HMOs. Efficacy of lower doses has rarely been tested. We assessed four HMO molecular species—2′Fucosyllactose (2′FL), Lacto-N-neotetraose (LNnT), 3′Sialyllactose (3′SL), and 6′Sialyllactose (6′SL)—at predicted doses from 0.3 to 5 g/day for 6-year-old children and adults (n = 6 each), using ex vivo SIFR® technology (Cryptobiotix, Ghent, Belgium). This technology employing bioreactor fermentation on fecal samples enables us to investigate microbial fermentation products that are intractable in vivo given their rapid absorption/consumption in the human gut. We found that HMOs significantly increased short-chain fatty acids (SCFAs), acetate, propionate (in children/adults), and butyrate (in adults) from predicted doses of 0.3–0.5 g/day onwards, with stronger effects as dosing increased. The fermentation of 6′SL had the greatest effect on propionate, LNnT most strongly increased butyrate, and 2′FL and 3′SL most strongly increased acetate. An untargeted metabolomic analysis revealed that HMOs enhanced immune-related metabolites beyond SCFAs, such as aromatic lactic acids (indole-3-lactic acid/3-phenyllactic acid) and 2-hydroxyisocaproic acid, as well as gut–brain-axis-related metabolites (γ-aminobutyric acid/3-hydroxybutyric acid/acetylcholine) and vitamins. The effects of low doses of HMOs potentially originate from the highly specific stimulation of keystone species belonging to, for example, the Bifidobacteriaceae family, which had already significantly increased at doses of only 0.5 g/day LNnT (adults) and 1 g/day 2′FL (children/adults). Full article
(This article belongs to the Special Issue Novel Metabolomics and Techniques for Metabolic Disorders in Intestinal Microbiota)
►▼ Show Figures

Figure 1

11 pages, 862 KiB  
Article
Differences in Fecal Short-Chain Fatty Acids between Alcoholic Fatty Liver-Induced Cirrhosis and Non-alcoholic (Metabolic-Associated) Fatty Liver-Induced Cirrhosis
by Xinlu Cao, Oksana Zolnikova, Roman Maslennikov, Maria Reshetova, Elena Poluektova, Arina Bogacheva, Maria Zharkova and Vladimir Ivashkin
Metabolites 2023, 13(7), 859; https://0-doi-org.brum.beds.ac.uk/10.3390/metabo13070859 - 19 Jul 2023
Cited by 4 | Viewed by 1201
Abstract
The objective of this study was to investigate the metabolic activity of the gut microbiota in cirrhosis due to different variants of fatty liver disease (alcoholic vs. non-alcoholic [metabolic-associated] one [AFLD and MAFLD]). The present study included 24 patients with alcoholic liver cirrhosis, [...] Read more.
The objective of this study was to investigate the metabolic activity of the gut microbiota in cirrhosis due to different variants of fatty liver disease (alcoholic vs. non-alcoholic [metabolic-associated] one [AFLD and MAFLD]). The present study included 24 patients with alcoholic liver cirrhosis, 16 patients with MAFLD-related cirrhosis, and 20 healthy controls. The level and spectrum of short-chain fatty acids (SCFAs) were determined via gas–liquid chromatography. All patients with cirrhosis showed a decrease in the total content of SCFAs (p < 0.001) and absolute content of acetate (p < 0.001), propionate (p < 0.001), butyrate (p < 0.001), and isovalerate (p < 0.001). In MAFLD cirrhosis, the metabolic activity of the microbiota was significantly altered compared to patients with alcoholic cirrhosis, as evidenced by a lower total SCFA content (p < 0.001) and absolute content of acetate (p < 0.001), propionate (p < 0.001), and butyrate (p < 0.001); a higher relative content of isovalerate (p < 0.001); and a higher IsoCn/Cn ratio (p < 0.001). Various clinical and laboratory parameters correlate differently with fecal SCFAs and their fractions in cirrhosis due to AFLD and MAFLD. SCFA-producing metabolic activity is reduced more in MAFLD cirrhosis than in alcoholic cirrhosis. According to the etiological factors of cirrhosis, disorders of this metabolic activity may be involved in different pathogenetic pathways. Full article
(This article belongs to the Special Issue Novel Metabolomics and Techniques for Metabolic Disorders in Intestinal Microbiota)
►▼ Show Figures

Graphical abstract

Review

Jump to: Research

24 pages, 2351 KiB  
Review
Interaction and Metabolic Pathways: Elucidating the Role of Gut Microbiota in Gestational Diabetes Mellitus Pathogenesis
by Lindong Mao, Biling Gao, Hao Chang and Heqing Shen
Metabolites 2024, 14(1), 43; https://0-doi-org.brum.beds.ac.uk/10.3390/metabo14010043 - 10 Jan 2024
Viewed by 1616
Abstract
Gestational diabetes mellitus (GDM) is a complex metabolic condition during pregnancy with an intricate link to gut microbiota alterations. Throughout gestation, notable shifts in the gut microbial component occur. GDM is marked by significant dysbiosis, with a decline in beneficial taxa like Bifidobacterium [...] Read more.
Gestational diabetes mellitus (GDM) is a complex metabolic condition during pregnancy with an intricate link to gut microbiota alterations. Throughout gestation, notable shifts in the gut microbial component occur. GDM is marked by significant dysbiosis, with a decline in beneficial taxa like Bifidobacterium and Lactobacillus and a surge in opportunistic taxa such as Enterococcus. These changes, detectable in the first trimester, hint as the potential early markers for GDM risk. Alongside these taxa shifts, microbial metabolic outputs, especially short-chain fatty acids and bile acids, are perturbed in GDM. These metabolites play pivotal roles in host glucose regulation, insulin responsiveness, and inflammation modulation, which are the key pathways disrupted in GDM. Moreover, maternal GDM status influences neonatal gut microbiota, indicating potential intergenerational health implications. With the advance of multi-omics approaches, a deeper understanding of the nuanced microbiota–host interactions via metabolites in GDM is emerging. The reviewed knowledge offers avenues for targeted microbiota-based interventions, holding promise for innovative strategies in GDM diagnosis, management, and prevention. Full article
(This article belongs to the Special Issue Novel Metabolomics and Techniques for Metabolic Disorders in Intestinal Microbiota)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-3
Back to TopTop